Deferiprone not beneficial for newly diagnosed Parkinson’s disease

by admin
0 comment

In newly diagnosed patients with Parkinson’s disease, deferiprone is associated with worse measures of Parkinsonism, according to a study published in the Dec. 1 issue of the journal. New England Journal of Medicine.

David Devos, MD, Ph.D., from the University of Lille, France, and colleagues step Two trials included newly diagnosed Parkinson’s disease patients who had never received levodopa. Participants received oral deferiprone (15 mg/kg body weight twice daily) or matching placebo for 36 weeks at a 1:1 ratio (186 Patience in each group). Dopaminergic therapy was withheld unless deemed necessary for symptom control.

The researchers found that symptom progression led to initiation of dopaminergic therapy in 22.0% and 2.7% of participants in the deferiprone and placebo groups, respectively. The mean Movement Disorder Association-sponsored modification of the Consolidated Parkinson’s Disease Rating Scale score at baseline was 34.3 in the deferiprone group, Placebo group They increased by 15.6 points and 6.3 points respectively.

Significant reductions in nigrostriatal iron content were observed in the deferiprone and placebo groups. The main serious adverse events of deferiprone were agranulocytosis and neutropenia in two participants and her three.

“Deferiprone was not associated with benefit compared with placebo in measures of Parkinson’s disease progression, and there was evidence of clinical deterioration,” the authors wrote. “Deferiprone was associated with adverse events. .”

ApoPharma and Chiesi provided deferiprone and placebo for the study.

For more information:
David Devos et al, Trial of deferiprone in Parkinson’s disease, New England Journal of Medicine (2022). DOI: 10.1056/NEJ Moa2209254

Douglas Galasko et al. Lack of benefit of iron chelation in early Parkinson’s disease. New England Journal of Medicine (2022). DOI: 10.1056/NEJMe2213120

Copyright © 2022 health day. all rights reserved.

Quote: Deferiprone Not Beneficial in Newly Diagnosed Parkinson’s Disease (Dec 1, 2022)

This document is subject to copyright. No part may be reproduced without written permission, except in fair trade for personal research or research purposes. Content is provided for informational purposes only.

You may also like

Leave a Comment